Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia

PHASE3CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

October 27, 2010

Primary Completion Date

October 24, 2012

Study Completion Date

October 24, 2012

Conditions
Essential Thrombocythemia (ET)
Interventions
DRUG

Anagrelide Hydrochloride

Subjects will be started at 1.0 mg per day and titrated as necessary.

Trial Locations (19)

05 010-8543

Akita University Hospital, Akita

13 113-8431

Juntendo University Hospital, Hongo 3-1-3

13 113-8677

Tokyo Metropolitan Cancer and Infectious diseases Center Kom, Honkomagome 3-18-22

13 113-8603

Nippon Medical School Hospital, Sendagi 1-1-5

12 260-8677

Chiba University Hospital, Chuo-ku Inohana 1-8-1

23 460-0001

NHO Nagoya Medical Center, Nagoya

01 060-8648

Hokkaido University Hospital, Sapporo

22 410-2295

Juntendo University Shizuoka Hospital, Nagaoka

259-1143

Tokai University Hospital, Isehara-shi

27 545-8586

Osaka City University Hospital, Osaka

10 371-8511

Gunma University Hospital, Showa-machi 3-39-15

13 152-8902

NHO Tokyo Medical Center, Higashigaoka 2-5-1

514-8507

Mie University Hospital, Tsu

889-1692

University of Miyazaki Hospital, Miyazaki

15 951-8566

Niigata Cancer Center Hospital, Chuo-ku Kawagishi-cho 2-15-3

33 700-8558

Okayama University Hospital, Okayama

27 565-0871

Osaka University Hospital, Suita-shi

770-8503

Tokushima University Hospital, Tokushima

13 160-8582

Keio University Hospital, Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Shire

INDUSTRY